Penetration of micafungin into the burn eschar in patients with severe burns

Junichi Sasaki, Satoshi Yamanouchi, Yukio Sato, Shinya Abe, Yotaro Shinozawa, Satoshi Kishino, Naoki Aikawa, Shingo Hori

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC 90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.

Original languageEnglish
Pages (from-to)93-97
Number of pages5
JournalEuropean Journal of Drug Metabolism and Pharmacokinetics
Volume39
Issue number2
DOIs
Publication statusPublished - 2014

Fingerprint

Burns
micafungin
Aspergillus
Candida
Intravenous Infusions
Healthy Volunteers
High Pressure Liquid Chromatography
Wounds and Injuries
Therapeutics

Keywords

  • Burn eschar penetration
  • Echinocandin antifungal agent
  • Micafungin
  • Pharmacokinetics

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology

Cite this

Penetration of micafungin into the burn eschar in patients with severe burns. / Sasaki, Junichi; Yamanouchi, Satoshi; Sato, Yukio; Abe, Shinya; Shinozawa, Yotaro; Kishino, Satoshi; Aikawa, Naoki; Hori, Shingo.

In: European Journal of Drug Metabolism and Pharmacokinetics, Vol. 39, No. 2, 2014, p. 93-97.

Research output: Contribution to journalArticle

Sasaki, Junichi ; Yamanouchi, Satoshi ; Sato, Yukio ; Abe, Shinya ; Shinozawa, Yotaro ; Kishino, Satoshi ; Aikawa, Naoki ; Hori, Shingo. / Penetration of micafungin into the burn eschar in patients with severe burns. In: European Journal of Drug Metabolism and Pharmacokinetics. 2014 ; Vol. 39, No. 2. pp. 93-97.
@article{1c18ba7af501483c86e37f10c716b6b3,
title = "Penetration of micafungin into the burn eschar in patients with severe burns",
abstract = "Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC 90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.",
keywords = "Burn eschar penetration, Echinocandin antifungal agent, Micafungin, Pharmacokinetics",
author = "Junichi Sasaki and Satoshi Yamanouchi and Yukio Sato and Shinya Abe and Yotaro Shinozawa and Satoshi Kishino and Naoki Aikawa and Shingo Hori",
year = "2014",
doi = "10.1007/s13318-013-0146-9",
language = "English",
volume = "39",
pages = "93--97",
journal = "European Journal of Drug Metabolism and Pharmacokinetics",
issn = "0378-7966",
publisher = "Springer Paris",
number = "2",

}

TY - JOUR

T1 - Penetration of micafungin into the burn eschar in patients with severe burns

AU - Sasaki, Junichi

AU - Yamanouchi, Satoshi

AU - Sato, Yukio

AU - Abe, Shinya

AU - Shinozawa, Yotaro

AU - Kishino, Satoshi

AU - Aikawa, Naoki

AU - Hori, Shingo

PY - 2014

Y1 - 2014

N2 - Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC 90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.

AB - Micafungin (MCFG) concentrations in the plasma and in burn eschar were investigated after daily intravenous infusion (1 h) of MCFG (200 mg) in three patients with severe burns. MCFG treatment was initiated more than 72 h after the burn injuries. The MCFG concentrations in the plasma were determined at the end of the first administration of MCFG, immediately before the second dosing, at the end of the MCFG infusion after at least 4 days from the initial treatment, and immediately before the subsequent dosing using high-performance liquid chromatography. In addition, the trough levels in burn eschar after both the initial administration and repeated administration were measured. The peak and trough levels in the plasma were comparable to or slightly lower than the reported values in healthy volunteers. The mean (range) MCFG concentrations in the burn eschar after initial administration and repeated administration were 1.41 μg/mL (<0.1-3.98 μg/mL) and 6.65 μg/mL (1.10-14.81 μg/mL), respectively. In most cases, the MCFG concentrations in the burn eschar, especially after repeated administration, were higher than the reported MIC 90 of MCFG against the clinically important pathogenic species of Candida and Aspergillus. These results suggest that MCFG is capable of penetrating burn eschar.

KW - Burn eschar penetration

KW - Echinocandin antifungal agent

KW - Micafungin

KW - Pharmacokinetics

UR - http://www.scopus.com/inward/record.url?scp=84902374085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902374085&partnerID=8YFLogxK

U2 - 10.1007/s13318-013-0146-9

DO - 10.1007/s13318-013-0146-9

M3 - Article

C2 - 23771854

AN - SCOPUS:84902374085

VL - 39

SP - 93

EP - 97

JO - European Journal of Drug Metabolism and Pharmacokinetics

JF - European Journal of Drug Metabolism and Pharmacokinetics

SN - 0378-7966

IS - 2

ER -